David Kim Portfolio
Invests via Paradigm Biocapital Advisors LP | Managed by Senai Asefaw, M.D., David Kim
Invests via Paradigm Biocapital Advisors LP
Managed by Senai Asefaw, M.D., David Kim
Automatically Tracked
David Kim Profile
With a strong foundation in technology and finance, David Kim has established himself as an influential figure in the startup ecosystem. His entrepreneurial journey began with the launch of multiple successful tech ventures, driving innovation in software solutions. As a seasoned operator, he emphasizes leveraging disruptive technologies to address market needs and create scalable business models. Kim's strategic leadership is evidenced by his ability to cultivate partnerships that accelerate growth and enhance competitive positioning within emerging sectors. Through mentorship roles and active investment participation, he remains committed to nurturing new talent and ideas that redefine industry standards.
With a strong foundation in technology and finance, David Kim has established himself as an influential figure in the startup ecosystem. His entrepreneurial journey began with the launch of multiple successful tech ventures, driving innovation in software solutions. As a seasoned operator, he emphasizes leveraging disruptive technologies to address market needs and create scalable business models. Kim's strategic leadership is evidenced by his ability to cultivate partnerships that accelerate growth and enhance competitive positioning within emerging sectors. Through mentorship roles and active investment participation, he remains committed to nurturing new talent and ideas that redefine industry standards.
Investment Philosophy & Strategy
David Kim's investment perspective thrives at the intersection of innovation and technology-driven growth. With a keen eye for identifying transformative startups, he actively seeks out companies poised to disrupt traditional markets. Emphasizing scalability, his approach combines rigorous analysis with an entrepreneurial mindset, focusing on building robust business models that respond dynamically to customer demands. His operational expertise allows him to assess potential partnerships and strategic alignments effectively, fostering environments ripe for rapid development. Kim champions ideas that challenge conventions and pave the way for future trends within the tech landscape.
David Kim's investment perspective thrives at the intersection of innovation and technology-driven growth. With a keen eye for identifying transformative startups, he actively seeks out companies poised to disrupt traditional markets. Emphasizing scalability, his approach combines rigorous analysis with an entrepreneurial mindset, focusing on building robust business models that respond dynamically to customer demands. His operational expertise allows him to assess potential partnerships and strategic alignments effectively, fostering environments ripe for rapid development. Kim champions ideas that challenge conventions and pave the way for future trends within the tech landscape.
Disclaimer: This Portfolio is derived from and computed based on publicly available data from SEC filings.
Gain and growth charts are calculated per selected timeframe:
259.65%
Gain +1.22%
Monthly
2.33%
Yearly
31.87%
Drawdown
44.26%
$5.54B
Equity
Holdings
$5.54B
Investment
$3.44B
$2.72B
Profit +$40.31M
Realized
$616.38M
Unrealized
$2.1B
Dividends
$0
Goals
Avg. 96.5% completed goals
Yearly
Gain > 5% 2026
Yearly
Gain < 20% 2026
Today
Compared To Yesterday
Gain
1.22%
Profit
$40.31M
Win %
79%
This Week
Compared To Last Week
Gain
0.73%
Profit
$40.31M
Win %
79%
This Month
Compared to last month
Gain
-1.51%
Profit
-$84.91M
Win %
79%
This Year
Compared to last year
Gain
4.65%
Profit
$246.06M
Win %
76%
TYRA Tyra Biosciences, Inc.
+13.8%
+$5.56M 
VRDN Viridian Therapeutics Inc.
+4.52%
+$6.45M 
ORKA Oruka Therapeutics, Inc.
+3.92%
+$7.76M 
VOR Vor Biopharma Inc.
+3.5%
+$1.36M 
TNGX Tango Therapeutics Inc.
+3.2%
+$4.83M 
KARD Kardigan, Inc.
+2.86%
+$477,000 
ACHV Achieve Life Sciences Inc.
+2.41%
+$841,815.52 
ERAS Erasca, Inc.
+1.76%
+$2.67M 
JBIO Jade Biosciences Inc.
+1.62%
+$828,647.45 
EDIT Editas Medicine Inc.
+1.48%
+$223,465 
MPLT MapLight Therapeutics, Inc.
+1.15%
+$102,877.8 
TARS Tarsus Pharmaceuticals Inc.
+0.81%
+$1.78M 
MBX MBX Biosciences, Inc.
+0.8%
+$1.18M 
OLMA Olema Pharmaceuticals Inc.
+0.69%
+$606,940.32 
RVMD Revolution Medicines Inc.
+0.66%
+$8.52M 
GMAB Genmab A/S Sponsored ADR
+0.55%
+$2.36M 
ALNY Alnylam Pharmaceuticals Inc
+0.53%
+$628,800 
EWTX Edgewise Therapeutics, Inc.
+0.49%
+$2.25M 
EYPT EyePoint Pharmaceuticals Inc.
+0.47%
+$57,807.94 
SYRE Spyre Therapeutics, Inc.
+0.22%
+$768,155.6 
PCVX Vaxcyte, Inc.
+0.12%
+$148,949.64 
APGE Apogee Therapeutics Inc.
0%
$0 
NUVL Nuvalent, Inc.
0%
$0 Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 512 | Longs Won 280/512 54% | Profit Factor 4.51 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $28.62M |
| Average Win $12.48M | Best Trade (Sep 09) $406.47M | Sharpe Ratio -40.65 |
| Average Loss -$3.34M | Worst Trade (Sep 02) -$50.83M | Z-Score 1.76 (92.21%) |
| Commissions $0 | Avg. Trade Length 11m 3w 1d | Expectancy $5.31M |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | 0.05% |
| Consecutive Losing Trades | 1,658 | 1,493 | 1,327 | 1,161 | 995 | 829 | 663 | 498 | 332 | 166 |
Hover over the desired column for a detailed explanation.
Returns
Overall, Monthly| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
| ACHV Achieve Life Sciences Inc. | 4.95M | $32.34M | $35.8M | - | $3.47M | 10.72% | +2.408% |
| ALNY Alnylam Pharmaceuticals Inc | 480,000 | $144.49M | $120M | - | -$24.5M | -16.96% | +0.527% |
| APGE Apogee Therapeutics Inc. | 1.58M | $96.94M | $212.92M | - | $115.98M | 119.65% | 0.0 |
 ASMB Assembly Biosciences Inc. | 1.55M | $46.58M | $45M | - | -$1.58M | -3.4% | -2.819% |
 BLTE Belite Bio, Inc. | 1.23M | $195.55M | $213.29M | - | $17.74M | 9.07% | -0.455% |
| EDIT Editas Medicine Inc. | 5.59M | $18.1M | $15.31M | - | -$2.79M | -15.43% | +1.481% |
| ERAS Erasca, Inc. | 9.55M | $23.08M | $154.33M | - | $131.25M | 568.7% | +1.763% |
| EWTX Edgewise Therapeutics, Inc. | 10.22M | $272.83M | $455.81M | - | $182.98M | 67.07% | +0.495% |
| EYPT EyePoint Pharmaceuticals Inc. | 2.89M | $47.95M | $12.28M | - | -$35.67M | -74.38% | +0.473% |
| GMAB Genmab A/S Sponsored ADR | 13.13M | $374.83M | $428.8M | - | $53.97M | 14.4% | +0.554% |
 INSM Insmed Inc. | 1.33M | $212.76M | $166.14M | - | -$46.61M | -21.91% | -3.176% |
 IVA Inventiva S.A. | 4M | $18.6M | $15.52M | - | -$3.08M | -16.56% | -3.483% |
| JBIO Jade Biosciences Inc. | 2.86M | $63.49M | $51.95M | - | -$11.54M | -18.18% | +1.621% |
| KARD Kardigan, Inc. | 900,000 | $21.46M | $17.14M | - | -$4.32M | -20.13% | +2.862% |
 LXEO Lexeo Therapeutics Inc. | 4.18M | $35.51M | $17.58M | - | -$17.93M | -50.49% | -0.941% |
| MBX MBX Biosciences, Inc. | 2.51M | $138.44M | $149.2M | - | $10.76M | 7.77% | +0.796% |
| MPLT MapLight Therapeutics, Inc. | 685,852 | $18.63M | $9.02M | - | -$9.61M | -51.58% | +1.154% |
| NUVL Nuvalent, Inc. | 5.92M | $436.34M | $734.39M | - | $298.06M | 68.31% | 0.0 |
| OLMA Olema Pharmaceuticals Inc. | 8.67M | $103.51M | $89.22M | - | -$14.29M | -13.8% | +0.685% |
| ORKA Oruka Therapeutics, Inc. | 2.14M | $76.43M | $205.87M | - | $129.44M | 169.36% | +3.919% |
No Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
FAQ
Which stocks have generated the highest profits for David Kim?
The largest contributions to the portfolio's profits come from the following stocks: argenx SE American Depositary Receipt - $96.4M, Alpine Immune Sciences Inc - $92.53M, Cogent Biosciences, Inc - $69.98M, Crinetics Pharmaceuticals Inc - $64M, and Erasca, Inc - $61.84M. These positions have been the main drivers of growth and have significantly impacted the investor's overall performance.
Which stocks have generated the largest losses for this investor?
The largest losses in the portfolio are associated with the following stocks: Janux Therapeutics Inc - $77.38M, Arvinas Inc - $61.12M, Vor Biopharma Inc - $37.73M, Immatics N.V - $28.92M, and Keros Therapeutics Inc - $24.52M. These positions have had the most negative impact on overall performance and highlight the weaker areas of the portfolio.
How stable are David Kim's monthly returns?
David Kim's monthly returns look highly volatile. The portfolio shows large month-to-month swings, and the broader risk profile suggests that performance can change sharply over short periods. This kind of pattern may suit users who are comfortable with significant fluctuations, but it is less likely to appeal to those who prefer steadier and more predictable results.
Can David Kim's strategy be considered aggressive or moderate?
David Kim's strategy can be considered aggressive. The combination of high drawdowns, elevated volatility, and/or concentrated positions suggests a willingness to accept significant risk in pursuit of higher long-term returns. This approach is generally more suitable for users who are comfortable with large fluctuations in portfolio value.
Should beginners follow David Kim's strategy?
David Kim's strategy is unlikely to be suitable for beginners. The portfolio shows signs of high risk, significant volatility, or structural complexity, which can make it difficult to follow and potentially stressful for less experienced users. This type of approach is generally better suited to more advanced investors.
